Patents by Inventor Mark E. Layton

Mark E. Layton has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20080287457
    Abstract: The present invention is directed to compounds which contain substituted naphthyridines which inhibit the activity of Akt, a serine/threonine protein kinase. The invention is further directed to chemotherapeutic compositions containing the compounds of this invention and methods for treating cancer comprising administration of the compounds of the invention. These substituted naphthyridines have unexpected advantageous properties when compared to other naphthyridines reported in PCT publication WO2003/086394, such unexpected advantageous properties may include increased cellular potency/solubility, greater selectivity, enhanced pharmacokinetic properties, lack of off target activity and so on.
    Type: Application
    Filed: December 9, 2005
    Publication date: November 20, 2008
    Inventors: Jeannie M. Arruda, Brian T. Campbell, Nicholas D.P. Cosford, Jacob M. Hoffman, Essa H. Hu, Mark E. Layton, Yiwei Li, Jun Liang, Kevin J. Rodzinak, Tony Siu, Brian A. Stearns, Lida R. Tehrani, Mark T. Bilodeau, Peter J. Manley
  • Patent number: 7452893
    Abstract: Compounds represented by Formula (I) or pharmaceutically acceptable salts thereof, are effective as NMDA/NR2B antagonists useful for treating neurological conditions such as, for example, pain, Parkinson's disease, Alzheimer's disease, epilepsy, depression, anxiety, ischemic brain injury including stroke, and other conditions.
    Type: Grant
    Filed: August 11, 2004
    Date of Patent: November 18, 2008
    Assignee: Merck & Co., Inc.
    Inventors: Wayne Thompson, Steven D. Young, Brian T. Phillips, Peter Munson, Willie Whitter, Nigel Liverton, Christine Dieckhaus, John Butcher, John A. McCauley, Charles J. McIntyre, Mark E. Layton, Philip E. Sanderson
  • Publication number: 20080161317
    Abstract: The instant invention provides for substituted naphthyridine compounds that inhibit Akt activity. In particular, the compounds disclosed selectively inhibit one or two of the Akt isoforms. The invention also provides for compositions comprising such inhibitory compounds and methods of inhibiting Akt activity by administering the compound to a patient in need of treatment of cancer.
    Type: Application
    Filed: December 4, 2007
    Publication date: July 3, 2008
    Inventors: Michael J. Kelly, Mark E. Layton, Philip E. Sanderson
  • Publication number: 20010024798
    Abstract: The present invention provides biomimetic compounds and libraries thereof, as well as methods for their production. In general, the inventive method involves the selection of a desired biological synthetic pathway and mimics that synthetic pathway utilizing modern synthetic tools. The structures formed from this method are preferably generated in fewer than four steps. These scaffold structures can then be functionalized to yield biomimetic compounds and libraries of compounds. In preferred embodiments, biomimetic compounds and libraries are generated from an oxidative phenolic coupling reaction. In other particularly preferred embodiments, the compounds and libraries of compounds are generated from cascade reactions to yield bicyclo [n.3.1] ring systems, medium ring systems, and fused ring systems.
    Type: Application
    Filed: April 19, 2001
    Publication date: September 27, 2001
    Inventors: Matthew D. Shair, Craig W. Lindsley, Henry E. Pelish, Scott M. Sheehan, Brian C. Goess, Mark E. Layton, Lawrence K. Chan, Chuo Chen, Nicholas J. Westwood